Moderna

Today we announced that three abstracts on our investigational mRNA therapeutics have been accepted for presentation at the 2025 European Society for Medical Oncology (ESMO) Congress, which will be held October 17-21, 2025, in Berlin, Germany. Read more: https://xmrrwallet.com/cmx.plnkd.in/egqK_X5h

Today we announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization for an updated formulation of the COVID-19 vaccine Spikevax®, targeting the SARS-CoV-2 variant LP.8.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older.   Read more: https://xmrrwallet.com/cmx.plnkd.in/ejxV-jqJ

For Jagjit Ludu, joining Moderna meant the chance to think differently and connect science to people in new ways. From launching clinician-focused docu-series to building AI-powered tools for bite-sized learning, he’s reshaping how Medical Affairs engages and informs. 💡 “Being a changemaker means hearing ‘no’ and persisting,” Jagjit shares. His work is proof that creativity and science can move together—and make an impact. Read more about Jagjit’s journey: https://xmrrwallet.com/cmx.plnkd.in/eex_9nSs

We are proud to have earned a top score on Disability:IN’s 2025 Disability Index and to be recognized for #DisabilityInclusion for the 4th year in a row! 🏆    Leading with belonging is essential to helping our people thrive. Thank you Disability:IN for this recognition and for your ongoing leadership in advancing disability inclusion across the business community. 

Today we announced that the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for Spikevax®, our COVID-19 vaccine, in children 6 months through 11 years of age who are at increased risk for COVID-19 disease. Our COVID-19 vaccine, mRNA-1273, was previously available for pediatric populations under Emergency Use Authorization.    Read more: https://xmrrwallet.com/cmx.plnkd.in/dxEgzjY9

Congratulations to our Chief Legal Officer, Shannon Thyme Klinger, on this well-deserved recognition. Shannon’s bold leadership and deep commitment to patients continues to inspire our teams and shape the future of medicine across Moderna and our industry.

Today we announced positive results from a Phase 3 efficacy study evaluating the relative vaccine efficacy against influenza illness of mRNA-1010, our seasonal influenza vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older.   Read more: https://xmrrwallet.com/cmx.plnkd.in/e5KneRqt

CMV Awareness Month in June highlights the impact of congenital cytomegalovirus (CMV), the most common congenital infection worldwide, affecting 1 in 200 newborns in the US and up to 12 in 200 in developing countries. As part of Moderna’s #StimulatingtheScience initiative, we’re recognizing peer-reviewed studies that are shaping the future of CMV awareness, surveillance and care.   The second article we’re proud to highlight this month is by Dr. Chelsea Lutz, PhD, MPH, CPH, et al., and is titled, “Updated National and State-Specific Prevalence of Congenital Cytomegalovirus Infection, United States, 2018–2022” This study presents the most recent national and state-specific estimates of congenital CMV (cCMV) prevalence in the U.S., adjusted for maternal age and demographic differences across populations. The findings reveal clear health disparities in cCMV burden by race, ethnicity, maternal age and geography—insights that are critical for informing more targeted and equitable public health strategies, screening programs and future vaccine efforts.   We thank the authors for their important contributions to the field that support efforts to reduce the burden of cCMV nationwide. Read the paper: https://xmrrwallet.com/cmx.plnkd.in/eC4-5-RN

mRNA medicines could be transformative. They can be personalized for a single patient, tailored for a rare disease or developed at scale for millions, as seen with the COVID-19 vaccine.    But how are these medicines made? Watch this video to explore the innovative process that starts with a DNA template and leads to groundbreaking medical advancements. You can also head to Module 1 on our free 'mRNAs as Medicines' course on Coursera to learn more. https://xmrrwallet.com/cmx.plnkd.in/dCtbvvDD  

June is CMV Awareness Month—a time dedicated to raising awareness about cytomegalovirus (CMV), the leading infectious cause of birth defects in the United States. As part of this effort, our #StimulatingtheScience initiative recognizes and celebrates important, peer-reviewed research that advances our understanding of CMV and supports efforts to improve prevention, diagnosis and care.   The first study we are recognizing for our initiative is by Dr. Mallory Baker, et al., and is titled, “Timing of Congenital Cytomegalovirus Diagnosis and Missed Opportunities”. This study sheds light on how delayed diagnoses of congenital CMV (cCMV) can result in missed opportunities for early treatment, monitoring and intervention. Nearly half of the infants in the cohort were not diagnosed until after 3 weeks of age, with some diagnoses occurring well after the onset of sensorineural hearing loss. The findings emphasize the importance of early screening strategies—including universal and expanded targeted approaches—to prevent diagnostic delays and improve developmental outcomes.   We thank Dr. Baker and her colleagues for their meaningful contribution to the field and for helping shape the case for improved cCMV detection and care pathways. Read the study: https://xmrrwallet.com/cmx.plnkd.in/eA3Vqrvx